HDAC2 Inhibitors Enhance Cognitive Function via Selective Isoform Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders, memory and cognitive function impairments, and other diseases lack effective therapeutic options that specifically target HDAC2, a key regulator of synaptic plasticity and memory formation.
Innovation Solution
Development of compounds that selectively inhibit HDAC2, which can be used to treat or prevent neurological disorders, memory or cognitive function impairments, and other diseases by enhancing synaptic and dendritic density in neuronal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonspecific HDAC inhibitors are used, then synaptic plasticity and long-term memory are enhanced, but selectivity for HDAC2 is lost leading to off-target effects
Solution Approach 1:
The patent segments the HDAC inhibitor class into specific subclasses that selectively target HDAC2. The compounds are designed with specific structural features (e.g., hydroxamic acid moieties combined with particular aromatic or heterocyclic groups) that confer selectivity for HDAC2 over other HDAC isoforms, thereby maintaining therapeutic effectiveness while achieving the needed selectivity.
Solution Approach 2:
The patent introduces specific local chemical features into the inhibitor molecules that interact with unique residues in the HDAC2 active site. These localized modifications (such as specific substituent patterns on aromatic rings or particular spatial arrangements of functional groups) enable the compounds to distinguish HDAC2 from other HDAC isoforms, resolving the contradiction between effectiveness and selectivity.
2Productivity
If HDAC2 is inhibited to enhance cognitive function, then memory formation is improved, but potential side effects from off-target HDAC inhibition may occur
Solution Approach 1:
The patent segments the HDAC inhibitor population into isoform-specific agents. By designing compounds that specifically inhibit HDAC2 while sparing other HDAC isoforms, the patent enables cognitive enhancement through HDAC2 inhibition without the off-target effects that plague nonspecific inhibitors, thus improving productivity while reducing harmful factors.
Solution Approach 2:
The patent employs carefully designed molecular structures as intermediaries that selectively bind to HDAC2. These compound intermediaries act as mediators between the therapeutic goal (cognitive enhancement) and the biological target (HDAC2), achieving the desired effect while avoiding interactions with other HDAC isoforms that would cause side effects.
Data Source
AI summary
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I), (II), (IIa), (III), (IV), (V), or (VI)) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.